In combining IL-7 administration with a GM-CSF-secreting tumor cell immunotherapy directed against colon carcinoma or malignant melanoma, Li et al. observed an increased number of activated dendritic cells, T cells in lymphoid tissues, and an increase of activated effector T cells in the tumor microenvironment. This evidence concerns the gene IL7 and melanoma.